Skip to content

Educational content only. Not investment advice: no price targets or buy and sell recommendations of our own.

Companies / Intellia Therapeutics

NTLA

Intellia Therapeutics

7 active clinical studies registered on ClinicalTrials.gov, the most advanced in Phase 3. Next estimated primary completion: Jul 2027.

Programmes

ProgrammeMost advancedConditionsPartnerSourcesChecked
NTLA-2001
nexiguran ziclumeran
 Phase 3? Transthyretin Amyloidosis (ATTR) With Cardiomyopathy; Neuromuscular Disease; Neuromuscular Diseases (NMD) and 3 more Regeneron Pharmaceuticals NCT06128629, NCT06672237
Company pipeline page		 27 October 2026
NTLA-2002
Biological NTLA-2002
 Phase 3? Hereditary Angioedema – NCT05120830, NCT06634420
Company pipeline page		 27 October 2026

Upcoming milestones announced by the company

WhenTypeMilestone, as stated by the companySourceChecked
H2 2026 Enrolment MAGNITUDE-2: Intellia Therapeutics expects to complete enrollment in the MAGNITUDE-2 trial for ATTRv-PN in the second half of 2026. Company press release, filed with the SEC 6 August 2026 27 October 2026
10 Mar 2027 FDA decision date (PDUFA) lonvo-z: Intellia Therapeutics reports PDUFA target action date for lonvo-z set for March 10, 2027. Company press release, filed with the SEC 8 September 2026 27 October 2026

Clinical studies

Primary completionPhaseStatusCondition and study
4 Apr 2024
passed
 Phase 1/2? Active, not recruiting Hereditary Angioedema
NTLA-2002 in Adults With Hereditary Angioedema (HAE) · NCT05120830
10 Feb 2026
passed
 Phase 3? Active, not recruiting Hereditary Angioedema
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) · NCT06634420
Jul 2027 Phase 3? Recruiting Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease
A Phase 3 Study of NTLA-2001 in ATTRv-PN · NCT06672237
Dec 2027 Phase 3? Recruiting Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) · NCT06128629
14 Aug 2034 Phase 1/2? Recruiting Hemophilia B
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B · NCT06379789
Mar 2038 N/A Enrolling by invitation Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 · NCT05697861
Apr 2040 N/A Enrolling by invitation Hereditary Angioedema
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 · NCT06262399

Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.

Recent news

Headlines from other publications, linked to the original. We do not rewrite or summarise them. Analyst ratings and price targets are the opinion of the cited source, not ours.